Who are somatostatin infusion's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Parathyroid Hormone (PTH), insulin-like growth factor I, continuation of oxytocin administration, ACTH, Adrenocorticotrophic hormone, Intravenous Oxytocin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/somatostatin-infusion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

somatostatin infusion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

somatostatin infusion (somatostatin infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peptide hormone. Area: Gastroenterology.

phase 3 Peptide hormone Somatostatin receptors (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

somatostatin infusion (somatostatin infusion) — Hospices Civils de Lyon. Somatostatin infusion activates somatostatin receptors on neuroendocrine and immune cells to inhibit hormone and cytokine secretion and reduce splanchnic blood flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
somatostatin infusion TARGET	somatostatin infusion	Hospices Civils de Lyon	phase 3	Peptide hormone	Somatostatin receptors (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5)
Parathyroid Hormone (PTH)	Parathyroid Hormone (PTH)	Takeda	marketed	Peptide hormone / PTH1 receptor agonist	PTH1 receptor (PTHR1)
insulin-like growth factor I	insulin-like growth factor I	Children's Hospital of Philadelphia	marketed	Growth factor; recombinant peptide hormone	IGF-1 receptor (IGF1R)
continuation of oxytocin administration	continuation of oxytocin administration	Assistance Publique - Hôpitaux de Paris	marketed	Peptide hormone / Oxytocin receptor agonist	Oxytocin receptor (OXTR)
ACTH	ACTH	Providence Health & Services	marketed	Corticotropin; peptide hormone	Melanocortin-2 receptor (MC2R)
Adrenocorticotrophic hormone	Adrenocorticotrophic hormone	University of Ottawa	phase 3	Peptide hormone	Melanocortin-2 receptor (MC2R)
Intravenous Oxytocin	Intravenous Oxytocin	University of Wisconsin, Madison	phase 3	Peptide hormone	Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peptide hormone class)

Hospices Civils de Lyon · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
University of Ottawa · 1 drug in this class
University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). somatostatin infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/somatostatin-infusion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab